Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study

Published:2019-09 Issue:7 Volume:7 Page:2277-2283.e2
ISSN:2213-2198
Container-title:The Journal of Allergy and Clinical Immunology: In Practice
language:en
Short-container-title:The Journal of Allergy and Clinical Immunology: In Practice

Author:

Pérez de Llano Luis A.,Cosío Borja G.,Domingo Christian,Urrutia Isabel,Bobolea Irina,Valero Antonio,Entrenas Costa Luis M.,Quirce Santiago,Barranco Pilar,Marina Malanda Nuria,Andrés Luis Prieto,Alvarez-Gutiérrez Francisco J.

Funder

Asthma Research Program of the Spanish Respiratory Society

Teva Pharmaceutical Industries

AstraZeneca

Teva

Chiesi

GlaxoSmithKline

Boehringer-Ingelheim

Novartis

Sanofi

Esteve

Almirall

Menarini

Takeda

Pfizer

Ferrer

Stallergenes

Alk-Abelló

Allergy Therapeutics

Hall Allergy

Inmunotek

Roche

Publisher

Elsevier BV

Subject

Immunology and Allergy

Reference26 articles.

1. Evolving concepts of asthma;Gauthier;Am J Respir Crit Care Med,2015

2. The prevalence of severe refractory asthma;Hekking;J Allergy Clin Immunol,2015

3. Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study;Chipps;J Allergy Clin Immunol,2012

4. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR);Schleich;Respir Med,2014

5. Care pathways for the selection of a biologic in severe asthma;Bousquet;Eur Respir J,2017

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan;Drugs;2024-06

2. Biologics for severe asthma and beyond;Pharmacology & Therapeutics;2023-12

3. Cost-effectiveness analysis of dupilumab versus omalizumab, mepolizumab, and benralizumab added to the standard of care in adults with severe asthma in Colombia;Expert Review of Pharmacoeconomics & Outcomes Research;2023-11-23

4. GEMA 5.3. Spanish Guideline on the Management of Asthma;Open Respiratory Archives;2023-10

5. Biological therapy management from the initial selection of biologics to switching between biologics in severe asthma;Tuberk Toraks;2023-03-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3